← Product Code [OCC](/submissions/MI/subpart-d%E2%80%94serological-reagents/OCC) · K081030 # MODIFICATION TO PROFLU+ ASSAY (K081030) _Prodesse, Inc. · OCC · May 2, 2008 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OCC/K081030 ## Device Facts - **Applicant:** Prodesse, Inc. - **Product Code:** [OCC](/submissions/MI/subpart-d%E2%80%94serological-reagents/OCC.md) - **Decision Date:** May 2, 2008 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 866.3980 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use The ProFlu™ Assay is a multiplex Real Time RT-PCR in vitro diagnostic test for the rapid and qualitative detection and discrimination of Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV) nucleic acids isolated and purified from nasopharyngeal (NP) swab specimens obtained from symptomatic patients. This test is intended for use to aid in the differential diagnosis of Influenza A, Influenza B and RSV viral infections in humans and is not intended to detect Influenza C. Negative results do not preclude influenza or RSV virus infection and should not be used as the sole basis for treatment or other management decisions. It is recommended that negative RSV results be confirmed by culture. Performance characteristics for Influenza A Virus were established when Influenza A/H3 and A/H1 were the predominant Influenza A viruses in circulation. When other Influenza A viruses are emerging, performance characteristics may vary. If infections with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens. ## Device Story ProFlu™ Assay is a multiplex Real Time RT-PCR test for qualitative detection of Influenza A, Influenza B, and RSV nucleic acids. Input: nasopharyngeal swab specimens. Process: nucleic acid isolation/purification using either Roche MagNA Pure LC or bioMérieux NucliSENS easyMAG systems, followed by RT-PCR amplification on Cepheid SmartCycler II. Output: qualitative detection/discrimination of viral targets. Used in clinical laboratories by trained personnel. Results aid differential diagnosis; negative results require clinical correlation and RSV culture confirmation. Benefits include rapid identification of respiratory viruses to guide clinical management. ## Clinical Evidence Prospective (891 samples) and retrospective clinical studies conducted during 2006-2007 season. Compared ProFlu+ Assay against rapid culture/DFA reference method. Prospective study sensitivity: Influenza A 100%, Influenza B 97.8%, RSV 89.5%. Specificity: Influenza A 92.6%, Influenza B 98.6%, RSV 94.9%. Reproducibility study across 3 sites showed 98% overall agreement. ## Technological Characteristics Multiplex Real Time RT-PCR assay. Utilizes oligonucleotide primers/probes for conserved viral sequences. Taqman chemistry (5'-3' exonuclease activity). Instrumentation: MagNA Pure LC or NucliSENS easyMAG for extraction; Cepheid SmartCycler II for amplification/detection. Internal control included for inhibition monitoring. ## Regulatory Identification A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses:(1) Influenza A and Influenza B; (2) Influenza A subtype H1 and Influenza A subtype H3; (3) Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B; (4) Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus; (5) Human Metapneumovirus; (6) Rhinovirus; and (7) Adenovirus. ## Special Controls *Classification.* Class II (special controls). The special controls are:(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;” (2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and (3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents. ## Predicate Devices - xTAG™ RVP (Respiratory Viral Panel) (k063765) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 1 # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: K081030 B. Purpose for Submission: Request for removal of the requirement for culture confirmation of influenza A and B negative sample results from intend use of K073029 and adding the use of the bioMerieux EasyMag nucleic acid purification method. C. Measurand: See K073029 D. Type of Test: See K073029 E. Applicant: Prodesse Incorporated F. Proprietary and Established Names: ProFlu™ Plus Common Name: Respiratory Viral Panel (RVP) Multiplex Nucleic Acid Detection Assay G. Regulatory Information: 1. Regulation section: 21 CFR 866.3980, Respiratory viral panel multiplex nucleic acid assay 2. Classification: Class II 3. Product code: OCC 4. Panel: Microbiology (83) H. Intended Use: 1. Intended use(s): The ProFlu™ Assay is a multiplex Real Time RT-PCR in vitro diagnostic test for the rapid and qualitative detection and discrimination of Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV) nucleic acids isolated and purified from nasopharyngeal (NP) swab specimens obtained from symptomatic patients. This test is intended for use to aid in the differential diagnosis of Influenza A, Influenza B and RSV viral infections in humans and is not intended to detect Influenza C. Negative results do not preclude influenza or RSV virus infection and should not be used as the sole basis for treatment or other management decisions. It is recommended that negative RSV results be confirmed by culture. Performance characteristics for Influenza A Virus were established when Influenza A/H3 and A/H1 were the predominant Influenza A viruses in circulation. When other Influenza A viruses are emerging, performance characteristics may vary. If infections with a novel Influenza A virus is suspected based on current clinical and {1} epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens. 2. Indication(s) for use: Same as Intended Use. 3. Special conditions for use statement(s): For prescription use only 4. Special instrument requirements: Cepheid SmartCycler II Real Time Instrument I. Device Description: See K073029 Materials Provided See K073029 Materials Required But Not Provided Plasticware and consumables ☐ Polyester, rayon or nylon tipped nasopharyngeal swabs ☐ RNase/DNase-free 1.5 mL polypropylene microcentrifuge tubes ☐ Sterile RNase/DNase-free filter or positive displacement micropipettor tips ☐ MagNA Pure LC System Disposables (Reagent Tubs, Reaction Tips, Tip Trays, Cartridges) or easyMAG System Disposables (Sample Vessels and Tips) ☐ Biohit Pipette Tips for use with easyMAG System ☐ Greiner Break Four uncoated plates for use with easyMAG System ☐ Cepheid PCR reaction tubes, 25 µL ☐ Parafilm® M or MagNA Pure LC Cartridge Seals Reagents ☐ Roche MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Cat. # 03038505001) for 192 isolations or bioMérieux NucliSENS easyMAG reagents (Buffer 1 Cat. # 280130, Buffer 2 Cat. # 280131, Buffer 3 Cat. # 280132, Magnetic Silica Cat. # 280133, and Lysis Buffer Cat. # 280134) ☐ Micro Test™ M4 Viral Transport Medium (Remel, Inc. Cat. # 12500) or BD Universal Viral Transport medium (UTM; Becton, Dickinson and Co. Cat. # 220220) ☐ Molecular Grade Water (RNase/DNase Free) {2} ☐ Extraction Control (e.g. previously characterized positive sample) ## Equipment ☐ – 70°C Freezer ☐ Roche MagNA Pure LC System with software version 3.0.11 or bioMérieux NucliSENS easyMAG System with Software version 1.0.1 ☐ Biohit multi-channel pipettor for use with easyMAG System ☐ Cepheid SmartCycler II Real Time Instrument with Dx Software version 1.7b ☐ Micropipettors (range between 1-10 µL, 10-200 µL and 100-1000 µL) ☐ Mini-centrifuge with adapter for Cepheid Reaction Tubes ☐ Cepheid cooling block ☐ Cepheid cooling block ## Interpretation of Specimen Results See K073029 ## J. Substantial Equivalence Information: 1. Predicate device name(s): xTAG™ RVP (Respiratory Viral Panel) Common Name: Respiratory Viral Panel (RVP) Multiplex Nucleic Acid Detection Assay 2. Predicate 510(k) number(s): k063765 3. Comparison with predicate: See K073029 ## K. Standard/Guidance Document Referenced (if applicable): See K073029 ## L. Test Principle: See K073029 ## M. Performance Characteristics (if/when applicable): ### Expected Values See K073029 ### Clinical Performance See K073029 {3} # Results from Prospective Study See K073029 # Reproducibility See K073029 and comparing the ProFlu+ reproducibility, defined in this study as the closeness of agreement of repeated testing where only the extraction conditions are changed (easyMAG vs. MagNA Pure). Table 1: Extraction equivalence reproducibility study – average $C_T$ values for both MagNA Pure LC (MP) and easyMAG (EM) across days | Virus and Level | Average \( C_T \)s | | Standard Deviation | | 95% Confidence Interval | | | --- | --- | --- | --- | --- | --- | --- | | | MP | EM | MP | EM | MP | EM | | IA Low | 31.43 | 29.90 | 0.35 | 0.15 | 31.21 - 31.65 | 29.81 - 29.99 | | IA Med | 29.22 | 27.72 | 0.23 | 0.18 | 29.08 - 29.36 | 27.61 - 27.83 | | RA Low | 28.69 | 27.19 | 1.07 | 0.88 | 28.03 - 29.35 | 26.64 - 27.74 | | RA Med | 25.91 | 24.9 | 0.64 | 0.36 | 25.51 - 26.31 | 24.68 - 25.12 | # Analytical Sensitivity Analytical sensitivity (LoD) as defined as the lowest concentration at which $\geq 95\%$ of all replicates tested positive, ranged from $10^{2} - 10^{-1}\mathrm{TCID}_{50} / \mathrm{mL}$ . See K073029 and determining and comparing the Limits of Detection (LoDs) for Influenza A, Influenza B, RSV A and RSV B on each automated extractor. Table 2: LoD Summary for both MagNA Pure LC (MP) and easyMAG (EM) | Organism | LoD TCID50/mL | | Positivity | | % Positive | | | --- | --- | --- | --- | --- | --- | --- | | | MP | EM | MP | EM | MP | EM | | Influenza A | 1 x 102 | 1 x 102 | 10/10 | 9/9a | 100% | 100% | | Influenza B | 1 x 101 | 1 x 101 | 9/10b | 10/10 | 90% | 100% | | RSV A | 1 x 101 | 1 x 101 | 10/10 | 10/10 | 100% | 100% | | RSV B | 1 x 101 | 1 x 101 | 10/10 | 10/10 | 100% | 100% | a One sample was positive for both IA (expected) and RSV(suspected contamination). The sample was still positive in both the IA and RSV channel after repeat testing in duplicate and therefore, was an invalid sample and was excluded from analysis. b One replicate was negative for IB on the MP only. Repeat testing in duplicate of the extracted nucleic acid gave positive results for IB (original data, not repeat was used for analysis). {4} Table 3: LoD Study – Average $C_T$ Values for both MagNA Pure LC (MP) and easyMAG (EM) | Organism | Concentration TCID50/mL | Number of Positive Samples | | Average CT | | | --- | --- | --- | --- | --- | --- | | | | MP | EM | MP | EM | | Influenza A | 1 x 102 | 10 | 9a | 32.98 | 31.53 | | | 1 x 101 | 8 | 5 | 38.06 | 38.04 | | | 1 x 100 | 0 | 0 | NAb | NAb | | Influenza B | 1 x 101 | 9c | 10 | 29.91 | 29.39 | | | 1 x 100 | 0 | 0 | NAb | NAb | | | 1 x 10-1 | 0 | 0 | NAb | NAb | | RSV A | 1 x 101 | 10 | 10 | 29.22 | 29.96 | | | 1 x 100 | 3 | 5 | 33.8 | 34.22 | | | 1 x 10-1 | 2 | 0 | 33.45 | NAb | | RSV B | 1 x 102 | 10 | 10 | 28.65 | 27.19 | | | 1 x 101 | 10 | 10 | 33.39 | 32.55 | | | 1 x 100 | 4 | 7 | 37.13 | 38.41 | a One sample was positive for both IA (expected) and RSV(suspected contamination). The sample was still positive in both the IA and RSV channel after repeat testing in duplicate and therefore, was an invalid sample and was excluded from analysis. b NA: Not Applicable. No positive samples for that specific target at the specific concentration. One replicate extraction was negative for IB on MP only. Repeat testing in duplicate of the extract gave positive results for IB. The repeat testing results were not included in the analysis for MP. # Reactivity See K073029 # Analytical Specificity See K073029 # Competitive Inhibition See K073029 # Carry-over/Contamination See K073029 # N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10. # O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OCC/K081030](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OCC/K081030) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com